Dateline City:
WHITEHOUSE STATION, N.J.
Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the companys anti-PD-1 immunotherapy; expects to complete application in first half of 2014.
Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant.
Evaluates the role of Mercks Animal Health and Consumer Care businesses in the companys strategy for long-term value creation; expects conclusions to be reached and action, if any, to be taken in 2014.
Divests assets, including a portion of the U.S. ophthalmics business, SAPHRIS U.S. marketing rights and Sirna Therapeutics, Inc.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today will report on the strategic and operating actions it is taking to
drive short- and long-term growth, including sharpening its focus in
core markets and therapeutic areas, advancing its innovative pipeline
and unlocking the value in non-core areas of its business.
Language:
English
Contact:
MerckMedia:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461Investor:Carol Ferguson, 908-500-1101Justin Holko, 908-423- 5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more